scholarly journals The effect of aerobic exercise in the maintenance treatment of depression

2015 ◽  
Vol 12 (S1) ◽  
pp. S-3-S-6
Author(s):  
P. Majumder ◽  
I. Sharma ◽  
P. Vostanis ◽  
C. Bone
Keyword(s):  
Aerobic Exercise ◽  
Maintenance Treatment ◽  
Depressive Disorders ◽  
Rating Scale ◽  
Antidepressant Medication ◽  
Evidence Base ◽  
Exercise Group ◽  
Treatment Of Depression ◽  
Further Development ◽  
Hamilton Rating Scale

We investigated the efficacy of aerobic exercise alongside antidepressant medication as an adjuvant maintenance treatment for depression. Fifty patients in remission were randomly assigned to either medication only or medication plus exercise. Assessment of psychopathology was made at 6-weekly intervals (for 24 weeks) using the Hamilton Rating Scale for Depression. The medication-plus-exercise group showed significantly more improvement at 12 and 24 weeks than the medication-only group. This study adds to a growing evidence base that suggests aerobic exercise is worthy of further development in the treatment of depressive disorders.

scholarly journals Antidepressant study design affects patient expectancy: a pilot study

2009 ◽  
Vol 40 (5) ◽  
pp. 781-788 ◽  
Author(s):  
B. Rutherford ◽  
J. Sneed ◽  
D. Devanand ◽  
R. Eisenstadt ◽  
S. Roose
Keyword(s):  
Rating Scale ◽  
Antidepressant Medication ◽  
Group Differences ◽  
Controlled Trials ◽  
Group Assignment ◽  
Treatment Conditions ◽  
Treatment Of Depression ◽  
Before And After ◽  
Hamd Score ◽  
Pilot Rct

BackgroundResponse to antidepressant medication is higher in comparator versus placebo-controlled randomized controlled trials (RCTs). Patient expectancy is an important influence on clinical outcome in the treatment of depression and may explain this finding. The results are reported from a pilot RCT studying expectancy and depression outcome in placebo-controlled versus comparator treatment conditions.MethodOut-patients aged 18–65 years with major depressive disorder (MDD) were enrolled in this 8-week RCT. Subjects were randomized to placebo-controlled (escitalopram or placebo) or comparator (escitalopram or citalopram) administration of antidepressant medication. Subjects reported their expected likelihood and magnitude of depression improvement before and after randomization using questions from the Credibility and Expectancy Scale (CES). A regressed change model of post-randomization expectancy of improvement was fit to the data to determine whether subjects in the comparator group reported greater expectancies of improvement than subjects in the placebo-controlled group.ResultsTwenty subjects with mean age 56.5±11.7 years, a baseline Hamilton Depression Rating Scale (HAMD) score of 24.2±5.3, baseline Beck Depression Inventory (BDI) score of 24.9±6.4 and baseline Clinical Global Impressions (CGI) – Severity score of 4.0±0.3 were enrolled in the study. Adjusting for other factors, the effect of group assignment on expected magnitude of improvement was significant and large (effect size 1.5). No group differences in expected likelihood of improvement were found.ConclusionsRandomization to comparator versus placebo-controlled administration of antidepressant medication produced greater expectancies of how much patients would improve during the trial. This expectancy difference may explain the higher response and remission rates that are observed in comparator versus placebo-controlled trials.

Pharmacological Treatment of Depression in Cancer Patients

1996 ◽  
Vol 169 (4) ◽  
pp. 440-443 ◽  
Author(s):  
Kees Van Heeringen ◽  
Milana Zivkov
Keyword(s):  
Cancer Patients ◽  
Rating Scale ◽  
Controlled Study ◽  
Systematic Research ◽  
Cancer Stage ◽  
Efficacy And Safety ◽  
Double Blind ◽  
Patients With Cancer ◽  
Treatment Of Depression ◽  
Hamilton Rating Scale

BackgroundDepression has a reported mean prevalence of 24% in patients diagnosed with cancer. However, little systematic research on the efficacy of antidepressants in patients with cancer has been performed.MethodThe efficacy and safety of mianserin were studied in 55 depressed women with breast cancer (stage I or II and without known metastases), in a randomised, double-blind, six-week, placebo-controlled study.ResultsStatistically significant differences in the decrease in score from baseline on the Hamilton Rating Scale for Depression and the number of responders, favouring mianserin, were present after 28 and 42 days of treatment Significantly more placebo-treated patients prematurely terminated the study due to lack of efficacy while the safety profile of mianserin was similar to that of placebo.ConclusionsTreatment with mianserin resulted in a significant improvement in depressive symptoms in cancer patients, and was well tolerated.

Correlations Between Neuroendocrine Disorders and Biochemical Brain Metabolites Alterations in Antidepressant Treatment

2018 ◽  
Vol 69 (3) ◽  
pp. 621-626
Author(s):  
Luminita Ageu ◽  
Cristina Talpos ◽  
Ghizela Kanalas ◽  
Simina Crisan ◽  
Carmen Lacramioara Zamfir ◽  
...  
Keyword(s):  
Children And Adolescents ◽  
Mr Spectroscopy ◽  
Depressive Disorders ◽  
Rating Scale ◽  
Antidepressant Treatment ◽  
Treatment Strategies ◽  
Antidepressant Medication ◽  
Brain Metabolites ◽  
Gamma Aminobutyric Acid ◽  
Pharmacogenetic Testing

We approach the theme of modern investigation and treatment strategies, based on biochemical, clinical-biological, metabolic, pharmacogenetic, neuro-imagistic, and neuroendocrine integrative correlations in the management of depressive disorders. Our main objective was to investigate: the biochemical brain metabolites [N-acetyl-aspartate (NAA), gamma-aminobutyric acid (GABA), aspartate (Asp), creatine (CR), glutamine (Gln), glicerophosphocholine (GPC), phosphocholine (PC), phosphocreatine (PCr), taurine (Tau), N-methyl-D-aspartate (N-MDA), serine, glycine, choline (Cho)]; the neuroimagistic and neurobiological markers and the metabolic abnormalities in correlation with the molecular pharmacogenetic testing in children and adolescents treated with antidepressant medication. Our research was conducted between 2009-2016 on 90 children and adolescents with depressive disorders -45 children-G1, who benefited of pharmacogenetic testing tailored pharmacotherapy, and 45 without pharmacogenetic testing-G2. The patients were also evaluated by MR spectroscopy at baseline and after pharmacotherapy. The efficacy of the chosen therapy in correlation with the pharmacogenetic testing was evaluated by the mean change in the CDRS (Child Depression Rating Scale) total scores, in the CGI-S/I (Clinical Global Impression Severity/Improvement), CGAS (Clinical Global Assessment of Functioning) and by the change of the relevant neurobiological markers and MR spectroscopy biochemical brain metabolites. Our results showed statistically significant differences in the clinical scores between the studied groups. Our research could represent a proof that the biochemical brain metabolites registered in depressive disorders modified values in the MR spectroscopy and the administration of antidepressants could determine metabolic and neuroendocrine abnormalities (changed lipid profiles, high insulin and plasma glucose levels, weight gain, obesity), especially when chosen without prior pharmacogenetic testing.

scholarly journals Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Siamak MahmoudianDehkordi ◽  
◽  
Ahmed T. Ahmed ◽  
Sudeepa Bhattacharyya ◽  
Xianlin Han ◽  
...  
Keyword(s):  
Selective Serotonin Reuptake Inhibitors ◽  
Rating Scale ◽  
Lipid Membrane ◽  
Antidepressant Medication ◽  
Methionine Sulfoxide ◽  
Therapeutic Benefit ◽  
Mechanisms Of Action ◽  
Research Network ◽  
One Carbon Metabolism ◽  
Hamilton Rating Scale

AbstractSelective serotonin reuptake inhibitors (SSRIs) are the first-line treatment for major depressive disorder (MDD), yet their mechanisms of action are not fully understood and their therapeutic benefit varies among individuals. We used a targeted metabolomics approach utilizing a panel of 180 metabolites to gain insights into mechanisms of action and response to citalopram/escitalopram. Plasma samples from 136 participants with MDD enrolled into the Mayo Pharmacogenomics Research Network Antidepressant Medication Pharmacogenomic Study (PGRN-AMPS) were profiled at baseline and after 8 weeks of treatment. After treatment, we saw increased levels of short-chain acylcarnitines and decreased levels of medium-chain and long-chain acylcarnitines, suggesting an SSRI effect on β-oxidation and mitochondrial function. Amines—including arginine, proline, and methionine sulfoxide—were upregulated while serotonin and sarcosine were downregulated, suggesting an SSRI effect on urea cycle, one-carbon metabolism, and serotonin uptake. Eighteen lipids within the phosphatidylcholine (PC aa and ae) classes were upregulated. Changes in several lipid and amine levels correlated with changes in 17-item Hamilton Rating Scale for Depression scores (HRSD17). Differences in metabolic profiles at baseline and post-treatment were noted between participants who remitted (HRSD17 ≤ 7) and those who gained no meaningful benefits (<30% reduction in HRSD17). Remitters exhibited (a) higher baseline levels of C3, C5, alpha-aminoadipic acid, sarcosine, and serotonin; and (b) higher week-8 levels of PC aa C34:1, PC aa C34:2, PC aa C36:2, and PC aa C36:4. These findings suggest that mitochondrial energetics—including acylcarnitine metabolism, transport, and its link to β-oxidation—and lipid membrane remodeling may play roles in SSRI treatment response.

A Comparative Double-Blind Trial of the New Antidepressant Caroxazone and Amitriptyline

1978 ◽  
Vol 6 (5) ◽  
pp. 388-394 ◽  
Author(s):  
S Cecchini ◽  
P Petri ◽  
R Ardito ◽  
S R Bareggi ◽  
A Torriti
Keyword(s):  
Clinical Trials ◽  
Rating Scale ◽  
Pharmacological Properties ◽  
Double Blind Trial ◽  
Double Blind ◽  
Blind Trial ◽  
End Of Treatment ◽  
Treatment Of Depression ◽  
Symptom Scores ◽  
Hamilton Rating Scale

On the grounds of pharmacological properties and preliminary clinical trials the efficacy of the new antidepressant caroxazone was compared to amitriptyline in the management of depression. Forty patients mostly suffering from a neurotic or anxious-neurotic depression were admitted to a double-blind trial. All patients completed the study. The Hamilton Rating Scale for Depression was used for the clinical assessment at the beginning, during and at the end of treatment. The trial lasted three weeks. A significant improvement was seen for both drugs after seven days on most symptom scores and on total symptom score. No significant differences were found either at seven days or at the end of treatment between the two drugs. There were no significant differences in the incidence and severity of side-effects. In conclusion, caroxazone appears as an effective and well tolerated drug in the treatment of depression.

Assessment of the severity of primary depressive illness: Wakefield self-assessment depression inventory

1971 ◽  
Vol 1 (2) ◽  
pp. 143-149 ◽  
Author(s):  
R. P. Snaith ◽  
S. N. Ahmed ◽  
S. Mehta ◽  
Max Hamilton
Keyword(s):  
Rating Scale ◽  
Depressive Illness ◽  
Practical Significance ◽  
Self Assessment ◽  
Male And Female ◽  
Positive Correlation ◽  
Female Patients ◽  
The Mean ◽  
Further Development ◽  
Hamilton Rating Scale

SUMMARYA self-assessment inventory for measuring severity of depressive illness is described, Its chief merits are brevity and simplicity. The correlation with the Hamilton Rating Scale is +0·87. At a cut-off level of 14–15 points 3% of patients and 7·5% of ‘Normals’ are misclassified. The mean scores for male and female patients do not differ significantly and the small positive correlation of score with age is of little practical significance. The limitations in this inventory are discussed but, despite them, it has practical value and merits further development.

scholarly journals Distinctive neurocognitive effects of repetitive transcranial magnetic stimulation and electroconvulsive therapy in major depression

2005 ◽  
Vol 186 (5) ◽  
pp. 410-416 ◽  
Author(s):  
Svenja C. Schulze-Rauschenbach ◽  
Uta Harms ◽  
Thomas E. Schlaepfer ◽  
Wolfgang Maier ◽  
Peter Falkai ◽  
...  
Keyword(s):  
Transcranial Magnetic Stimulation ◽  
Major Depression ◽  
Electroconvulsive Therapy ◽  
Magnetic Stimulation ◽  
Rating Scale ◽  
Repetitive Transcranial Magnetic Stimulation ◽  
Memory Complaints ◽  
Treatment Of Depression ◽  
Psychotic Major Depression ◽  
Hamilton Rating Scale

BackgroundStudies have compared electroconvulsive therapy (ECT) and repetitive transcranial magnetic stimulation (rTMS) with regard to clinical efficacy in the treatment of depression, but no study has yet addressed the differential impact on cognition.AimsTo compare the neurocognitive effects of unilateral ECT and rTMS.MethodThirty patients with treatment-refractory non-psychotic major depression received an average of ten treatments with either unilateral ECT or left prefrontal rTMS and were assessed for objective and subjective cognitive impairments before and about a week after treatment.ResultsTreatment response was comparable (46% of the ECT group and 44% of the rTMS group showed a reduction of 50% or more in Hamilton Rating Scale for Depression scores). In patients treated with rTMS, cognitive performance remained constant or improved and memory complaints alleviated, whereas in the ECT group memory recall deficits emerged and memory complaints remained.ConclusionsIn contrastto unilateral ECT, rTMS has no adverse memory effects.

A critical evaluation of the role of cognitive behaviour therapy in children and adolescents with depression

2009 ◽  
Vol 2 (2) ◽  
pp. 83-91 ◽  
Author(s):  
Maura Delaney
Keyword(s):  
Children And Adolescents ◽  
Cognitive Behaviour Therapy ◽  
Depressive Disorders ◽  
Critical Evaluation ◽  
Evidence Base ◽  
Current Evidence ◽  
Behaviour Therapy ◽  
Treatment Of Depression ◽  
Cognitive Behaviour ◽  
Current Evidence Base

AbstractDepressive disorders are relatively common in adolescents although less so in younger children. They accrue significant morbidity and frequent long-term sequelae as well as increased suicide risk in sufferers. Evidence-based treatment of depression in children and adolescents is the subject of intense investigation and debate. This article reviews the current evidence base for cognitive behaviour therapy in this group and makes recommendations for further areas of research.

Treatment of Depression Using Sleep Electroencephalogram Modulated Repetitive Transcranial Magnetic Stimulation

2011 ◽  
Vol 26 (S2) ◽  
pp. 1142-1142
Author(s):  
M. He ◽  
Z. Gu ◽  
X. Wang ◽  
H. Shi
Keyword(s):  
Transcranial Magnetic Stimulation ◽  
Magnetic Stimulation ◽  
Rating Scale ◽  
Repetitive Transcranial Magnetic Stimulation ◽  
Animal Experiments ◽  
Treatment Of Depression ◽  
Psychoactive Medication ◽  
Before And After ◽  
To Receive ◽  
Hamilton Rating Scale

Background and purposeThe conventional repetitive transcranial magnetic stimulation (rTMS) has some inadequate of efficacy weak and inadequate for the treatment of depression, easy symptomatic recurrence when stop the treatment. Ours invented the device of sleep electroencephalogram-modulated rTMS (SEM-rTMS) were safe and effective by proved of the animal experiments and clinical pre-test for the treatment of depression. The purpose of this study was to examine the efficacy and safety of SEM-rTMS for the treatment of depression.MethodsAfter 7 days without psychoactive medication, 164 patients with clinically defined depression, were randomly assigned to receive SEM-rTMS (N = 57), conventional rTMS (C-rTMS (N = 55), or sham-rTMS (N = 52) for 30 minutes/time/day for 10 days. Before and after scores on the 24-item Hamilton rating scale for depression (HAMD-24) and the clinical outcome at the 10th-day of therapy for all subjects were analyzed.ResultsTwenty two cases in the SEM-rTMS group improved mood as compared to 6 in the C-rTMS group and 2 in the sham-rTMS group (c2 = 15.89, p = 0.0004). After completion of the rTMS phase of the protocol, a (51 ± 5) % reduction of HAMD-24 scores from the baseline in the SEM-rTMS group compared with a (34 ± 4)% in the C-rTMS group ((q = 26.09, p = 0.001) and a (14 ± 3)% in Sham-rTMS group (q = 57.53,p = 0.000). The 88% total efficacy ratio in the SEM-rTMS group was significant higher than 68% in the C-rTMS group and 20% in the sham-rTMS group (c2 = 12.01, p = 0.0025). No significant side effects were noted.ConclusionIt is efficient and safe to treat depression with repetitive transcranial magnetic stimulation. (The registration. No: ChiCTR-TRC-00000438).

Sign in / Sign up

Export Citation Format

Share Document